Sign In
Buy DYAI
$1.05
-0.0200 (-1.87%)
At Close: Jul 31, 2026
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2021 Results - Earnings Call Transcript
10:02pm, Tuesday, 29'th Mar 2022
Dyadic International's (DYAI) CEO Mark Emalfarb on Q4 2021 Results - Earnings Call Transcript
Dyadic Reports 2021 Year End Results and Recent Company Progress
08:00pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
JUPITER, Fla., March 29, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focuse
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
08:30pm, Tuesday, 15'th Mar 2022 GlobeNewswire Inc.
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focuse
Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022
04:30pm, Tuesday, 15'th Mar 2022
JUPITER, Fla., March 15, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
04:02pm, Tuesday, 15'th Feb 2022 Zacks Investment Research
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
Phirbo's (PAHC) Dyadic Deal to Fortify Animal Vaccine Wing
12:20pm, Tuesday, 15'th Feb 2022
Per the exclusive agreement, Phirbo (PAHC) together with Dyadic will continue development work to find a vaccine candidate using Dyadic's C1 cells.
Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine
01:30pm, Thursday, 10'th Feb 2022 GlobeNewswire Inc.
The exclusive license agreement between Dyadic and Phibro utilizes Dyadic engineered C1-cells to produce specific targeted antigens for development and commercialization of a poultry vaccine for a tar
Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
01:30pm, Monday, 07'th Feb 2022 GlobeNewswire Inc.
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying
Dyadic International's CEO Mark Emalfarb to Present at BIO CEO & Investor Conference
08:30am, Monday, 07'th Feb 2022
JUPITER, Fla., Feb. 07, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying an
Dyadic says C1-cell platform shows potential to develop synthetic cannabinoids
05:31pm, Thursday, 20'th Jan 2022 Seeking Alpha
Dyadic International <> said its C1-cells have been engineered to show the potential to manufacture therapeutically viable and commercially useful cannabis compounds
Dyadic Introduces Novel Method to Produce Synthetic Cannabinoids and Precursors Utilizing C1 Cell Line Production Platform and Patent Pending Process
01:30pm, Thursday, 20'th Jan 2022 GlobeNewswire Inc.
JUPITER, Fla., Jan. 20, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
Week 1 MDA Breakout Stocks - January 2022: Short-Term Picks To Give You An Edge
12:35pm, Sunday, 02'nd Jan 2022
Two sample Breakout Stocks for Week 1 with better than 10% short-term upside potential and a Dow stock pick. This past week 1 stock beat 10% peak gains with AEHR +27.2% and METC +8.6% with Momentum Ga
Dyadic Announces a NIIMBL Coronavirus Grant Under the White House’s American Rescue Plan
02:12pm, Wednesday, 22'nd Dec 2021 GlobeNewswire Inc.
JUPITER, Fla., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused
Dyadic International (NASDAQ:DYAI) Research Coverage Started at HC Wainwright
06:40am, Monday, 20'th Dec 2021 Dakota Financial News
HC Wainwright initiated coverage on shares of Dyadic International (NASDAQ:DYAI) in a research report released on Friday morning, Price Targets.com reports. The firm issued a buy rating and a $7.00 target price on the biotechnology companys stock. NASDAQ DYAI opened at $4.59 on Friday. Dyadic International has a 52 week low of $3.15 and a []
